Literature DB >> 21546862

PharmGKB summary: citalopram pharmacokinetics pathway.

Katrin Sangkuhl1, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21546862      PMCID： PMC3349993          DOI： 10.1097/FPC.0b013e328346063f

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  56 in total

1.  Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.

Authors:  U Jeppesen; L F Gram; K Vistisen; S Loft; H E Poulsen; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Neurobiological mechanisms involved in antidepressant therapies.

Authors:  M Briley; C Moret
Journal:  Clin Neuropharmacol       Date:  1993-10       Impact factor: 1.592

3.  The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.

Authors:  J Hyttel; K P Bøgesø; J Perregaard; C Sánchez
Journal:  J Neural Transm Gen Sect       Date:  1992

4.  Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

Authors:  Bang-Ning Yu; Guo-Lin Chen; Nan He; Dong-Sheng Ouyang; Xiao-Ping Chen; Zhao-Qian Liu; Hong-Hao Zhou
Journal:  Drug Metab Dispos       Date:  2003-10       Impact factor: 3.922

5.  Preliminary studies of the kinetics of citalopram in man.

Authors:  K F Overø
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

6.  Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response.

Authors:  Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Chin B Eap; Patricia Jiménez-Vasquez; Marlyse Brawand-Amey; Pierre Baumann
Journal:  J Clin Psychopharmacol       Date:  2004-06       Impact factor: 3.153

7.  Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.

Authors:  S H Sindrup; K Brøsen; M G Hansen; T Aaes-Jørgensen; K F Overø; L F Gram
Journal:  Ther Drug Monit       Date:  1993-02       Impact factor: 3.681

8.  Simultaneous determination of citalopram and its metabolites by high-performance liquid chromatography with column switching and fluorescence detection by direct plasma injection.

Authors:  E Matsui; M Hoshino; A Matsui; A Okahira
Journal:  J Chromatogr B Biomed Appl       Date:  1995-06-23

9.  The kinetics of citalopram: single and multiple dose studies in man.

Authors:  P Kragh-Sørensen; K F Overø; O L Petersen; K Jensen; W Parnas
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1981-01

Review 10.  Pharmacology and pharmacokinetics of citalopram and other SSRIs.

Authors:  P Baumann
Journal:  Int Clin Psychopharmacol       Date:  1996-03       Impact factor: 1.659
View more
  10 in total

1.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 2.  The role of cytochromes P450 in the metabolism of selected antidepressants and anxiolytics under psychological stress.

Authors:  Nina Zemanova; Pavel Anzenbacher; Eva Anzenbacherova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2022-04-12       Impact factor: 1.245

3.  Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder.

Authors:  M S Zastrozhin; VYu Skryabin; F Rwere; A E Petukhov; E P Pankratenko; S A Pozdniakov; V A Ivanchenko; V V Noskov; I A Zaytsev; N V Vinokurova; D S Horyaev; R V Vlasovskih; E A Bryun; D A Sychev
Journal:  Psychopharmacol Bull       Date:  2022-06-27

4.  Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.

Authors:  Thu-Lan T Luong; Chelsea N Powers; Brian J Reinhardt; Peter J Weina
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-06-14

5.  Improving response inhibition systems in frontotemporal dementia with citalopram.

Authors:  Laura E Hughes; Timothy Rittman; Ralf Regenthal; Trevor W Robbins; James B Rowe
Journal:  Brain       Date:  2015-05-21       Impact factor: 13.501

6.  Comparison of cannabidiol to citalopram in targeting fear memory in female mice.

Authors:  Zackary T Montoya; Amy L Uhernik; Jeffrey P Smith
Journal:  J Cannabis Res       Date:  2020-12-11

7.  Citalopram intoxication in four week old infant.

Authors:  Jo-Anne Janson; Arthur T M Wasylewicz; Marianne Eijkemans; Marieke Kerskes
Journal:  BMC Pediatr       Date:  2020-12-07       Impact factor: 2.125

8.  Selective serotonin reuptake inhibition modulates response inhibition in Parkinson's disease.

Authors:  Zheng Ye; Ellemarije Altena; Cristina Nombela; Charlotte R Housden; Helen Maxwell; Timothy Rittman; Chelan Huddleston; Charlotte L Rae; Ralf Regenthal; Barbara J Sahakian; Roger A Barker; Trevor W Robbins; James B Rowe
Journal:  Brain       Date:  2014-02-27       Impact factor: 13.501

9.  Modulation of brain activation during executive functioning in autism with citalopram.

Authors:  Robert H Wichers; James L Findon; Auke Jelsma; Vincent Giampietro; Vladimira Stoencheva; Dene M Robertson; Clodagh M Murphy; Grainne McAlonan; Christine Ecker; Katya Rubia; Declan G M Murphy; Eileen M Daly
Journal:  Transl Psychiatry       Date:  2019-11-11       Impact factor: 6.222

10.  Atomoxetine and citalopram alter brain network organization in Parkinson's disease.

Authors:  Robin J Borchert; Timothy Rittman; Charlotte L Rae; Luca Passamonti; Simon P Jones; Deniz Vatansever; Patricia Vázquez Rodríguez; Zheng Ye; Cristina Nombela; Laura E Hughes; Trevor W Robbins; James B Rowe
Journal:  Brain Commun       Date:  2019-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.